Meeting
2021 ASCO Annual Meeting
Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).
Authors
Chao Lyu
Thoracic Surgery II, Peking University Cancer Hospital, Beijing, China
Chao Lyu , Wentao Fang , Haitao Ma , Jia Wang , Wenjie Jiao , Rui Wang , Nan Wu , Shi-Dong Xu , Yue Yang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
ChiCTR1800016948
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8524)
DOI
10.1200/JCO.2021.39.15_suppl.8524
Abstract #
8524
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of osimertinib in patients with NSCLC and uncommon tumoral EGFR mutations: A systematic review and meta-analysis.
First Author: Jonathan N. Priantti
Poster
2024 ASCO Annual Meeting
High-dose furmonertinib in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study.
First Author: Haiyang Chen
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2023 ASCO Annual Meeting
Dacomitinib for patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations: Do mutation patterns matter?
First Author: Hong-Shuai Li